Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...
Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...
5d
MedPage Today on MSNYoung Patient Dies After Receiving New Gene Therapy for Duchenne Muscular DystrophyA young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...
Sebastien Beauzile, 21, is the first New Yorker to have received the breakthrough Lyfgenia treatment, according to the New ...
Sarepta Therapeutics said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for a rare muscular dystrophy.
2don MSN
An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment.
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.
3h
Zacks Investment Research on MSNHow to Play SRPT Stock After Patient Death Post DMD Therapy InfusionShares of Sarepta Therapeutics SRPT plunged nearly 24% last week after the company reported the death of a patient following ...
It was thought that a transplant would be the only option for Tomas, until he was enrolled on to the groundbreaking gene ...
The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but ...
Although cystic fibrosis is a single gene mutation, there are more than 1,000 different ways the CFTR gene can mutate in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results